International Journal of Colorectal Disease · 2014 · Clinical trial · PMID 25331030
Limitations: Disease-specific study cited by FDA; not a performance or anti-aging trial.
Explore the library
Limited human evidenceSynthetic pentapeptide secretagogue
Ipamorelin
Ipamorelin is a synthetic pentapeptide developed as a growth hormone secretagogue. Its research history includes preclinical endocrine work and a separate clinical gastrointestinal-motility study.
Also indexed as: NNC-26-0161
A clear starting point
Ipamorelin is a synthetic pentapeptide developed as a growth hormone secretagogue. Its research history includes preclinical endocrine work and a separate clinical gastrointestinal-motility study.
Systems mapping shows biological relevance, not a treatment recommendation or a patient CPI score.
No validated chemical structure is displayed in this edition.
How it works
Ghrelin / GH–IGF-1
Ipamorelin is a synthetic pentapeptide developed as a growth hormone secretagogue. Its research history includes preclinical endocrine work and a separate clinical gastrointestinal-motility study.
- Targets & processes
- Ghrelin / GH–IGF-1
- Systems & tissues
- See the pathway description; category links describe research relevance, not demonstrated treatment effects.
What does the evidence show?
GH signaling and gastrointestinal motility research.
What this does not establish
The foundational linked study is preclinical. A separate human postoperative-ileus trial does not establish anti-aging or recovery benefit.
European journal of endocrinology · 1998 · Cell / animal study · PMID 9849822
Citation metadata from PubMed, a service of the U.S. National Library of Medicine, NIH. A citation match is not a guarantee of study quality. Abstracts are not full-text reviews.
Safety is a separate question
FDA notes serious adverse events including deaths in an intravenous motility study and insufficient safety information for other injectable routes; this does not by itself establish causality.
Contraindications & cautions
Not an exhaustive contraindication review. FDA notes serious adverse events including deaths in an intravenous motility study and insufficient safety information for other injectable routes; this does not by itself establish causality.
Medication & supplement interactions
Interaction information is incomplete. FDA notes serious adverse events including deaths in an intravenous motility study and insufficient safety information for other injectable routes; this does not by itself establish causality.
Regulatory status · United States
Not FDA-approved. No FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval.
Read the official sourceThis is not an exhaustive safety list. Regulatory status varies by jurisdiction and product; investigational use is not approval.
Make the science interactive
A dedicated lesson has not been published for this ingredient yet. Explore the cited profile or ask the instructor.
Your scientific classroom
Ask the IW Science Instructor
Basic level · Published sources only · AI evidence check
Ask about general science. Do not enter names, personal health details or medication lists. This is not a clinical consultation. Discussion stays in this browser’s private learning session for up to 90 days.
All medications and therapies discussed are for educational purposes only. Prescriptions are determined independently by the licensed clinician following a medical evaluation. There is no guarantee that any medication or peptide will be prescribed.
IW Interactive Learning Engine · Adapted from stable OpenMAIC v1.2.1. Open-source license
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.
Education only. Confidence labels are not formal systematic evidence grades. No patient record is used.